Compare Elanco Animal Health Incorporated Common Stock (ELAN) vs SS&C Technologies Holdings Inc. Common Stock (SSNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elanco Animal Health Incorporated Common Stock vs SS&C Technologies Holdings Inc. Common Stock — how do they compare? Elanco Animal Health Incorporated Common Stock trades at $22.68 (market cap $11.27B), while SS&C Technologies Holdings Inc. Common Stock trades at $82.08 (market cap $19.25B). The key difference: SS&C Technologies Holdings Inc. Common Stock is the larger of the two by market cap, and SS&C Technologies Holdings Inc. Common Stock pays a 1.46% dividend while Elanco Animal Health Incorporated Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Elanco Animal Health Incorporated Common Stock for 6 Days and SS&C Technologies Holdings Inc. Common Stock for 0 Days on average.
| ELAN | SSNC | |
|---|---|---|
Market Cap | $11.27B | $19.25B |
Volume | 4,942,915 | 1,341,767 |
Sector | Health | Technology |
52-Week High | $26.84 | $89.62 |
52-Week Low | $19.80 | $62.05 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $14.65B | $26.59B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELAN trades at $22.41, down 0.66% today, with a bearish technical signal from moving averages. The company reported a net loss of $232 million in 2025, though revenue grew to $4.72 billion. Recent earnings beats and a 71% analyst buy rating reflect optimism around new product launches like Zenrelia and deleveraging plans discussed at recent conferences.
The outlook hinges on execution of growth initiatives to achieve profitability. Upside exists if new products gain market share as projected, but risks include persistent losses, competitive pressures, and high debt. The consensus price target of $28.00 suggests 25% potential upside from current levels.
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Elanco Animal Health Incorporated Common Stock
Elanco develops medicines, vaccines, and other health products for pets and livestock. Its products address prevention and treatment of animal diseases.
Read more on ELAN →About SS&C Technologies Holdings Inc. Common Stock
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →
